Friday, July 10, 2026

pharma · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Bayer | Pharmaceuticals

Bayer Australia is a pharma organization headquartered in Pymble, AU. Primary therapeutic focus areas include Transthyretin Amyloid Cardiomyopathy (ATTR-CM). NovaPharmaNews links 2 clinical program(s), 10 drug profile(s)

Berlin, DE HQ
4 Employees
TGA registrant Type
Company details
Status
Public
HQ
Berlin, DE
Employees
4
Programs
2
Drugs
15
Patents
1

Quick answer

Bayer Australia is a pharma organization headquartered in Pymble, AU. Primary therapeutic focus areas include Transthyretin Amyloid Cardiomyopathy (ATTR-CM). NovaPharmaNews links 2 clinical program(s), 10 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1), phase 1 (1).

Company snapshot

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. The Pharmaceuticals Division of Bayer focuses on prescription products for women’s healthcare, cardiology, oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessa

  • 16 approved product(s) across US/EU regulatory metadata.
  • 2 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Bayer | Pharmaceuticals. Not investment advice.

Lead pipeline drugs

Active clinical programs

  • 22049 Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression
    Phase 1
  • BEYONTTRA 356 mg film-coated tablets Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Approved

Momentum

Proprietary activity score for Bayer | Pharmaceuticals.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Bayer | Pharmaceuticals.

  1. Clinical update

    22049 — Phase 1

  2. Clinical update

    BEYONTTRA 356 mg film-coated tablets — Approved

  3. Patent grant

    Method of treating parasites

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Bayer | Pharmaceuticals?

    Bayer Australia is a pharma organization headquartered in Pymble, AU. Primary therapeutic focus areas include Transthyretin Amyloid Cardiomyopathy (ATTR-CM). NovaPharmaNews links 2 clinical program(s), 10 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA

  • Is Bayer | Pharmaceuticals publicly traded?

    Bayer | Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Bayer | Pharmaceuticals develop or market?

    We link 15 drug profile(s) where Bayer | Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bayer-schering-pharma-ag#company-drugs.

  • What are the latest developments for Bayer | Pharmaceuticals?

    In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Bayer | Pharmaceuticals focus on?

    Bayer | Pharmaceuticals focuses on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Cardiology
6
Others
6
Oncology
1